Outlook Sees Finish Line For Ophthalmic Bevacizumab

The US FDA Issued CRL Last Year Over CMC Issues And Lack Of Evidence

 
• By Urtė Fultinavičiūtė
Man walking a tightrope between two buildings
Outlook’s product would be the first approved ophthalmic formulation of bevacizumab • Source: Shutterstock

More from Biosimilars

More from Products